Bots, editor, reviewer, Administrators
13,951
edits
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==December 2023== | |||
; [[BELINDA]]: New summary #489: Tisa-cel vs. ASCT in R/R DLBCL | |||
==November 2023== | ==November 2023== | ||
; [[SUSTAIN-6]]: New summary #488: GLP-1 in DM if high CVD risk | ; [[SUSTAIN-6]]: New summary #488: GLP-1 in DM if high CVD risk |